VELARIQ® (oxybutynin hydrochloride) is indicated for the suppression of neurogenic detrusor overactivity (NDO) in children from 6 years of age and adults, who are managing bladder emptying by clean intermittent catheterisation, not adequately managed with oral anticholinergics.1
1 ml solution contains 1 mg oxybutynin hydrochloride. One scaled prefilled ready-to-use syringe with 10 ml solution contains 10 mg oxybutynin hydrochloride.1
Paediatric population
Dose recommendations in the following age groups
Age group | Age [years] | Recommended daily starting dose [mg] | Recommended total daily dose [mg] |
---|---|---|---|
Children | 6 - 12 | 2 | 2 - 30 |
Adolescents | 12 - 18 | 10 | 10 - 40 |
Adults | 19 - 65 | 10 | 10 - 40 |
Elderly (from 65 years)* | from 65 | 10 | 10 - 30 |
*As with other anticholinergic drugs caution should be observed in frail and elderly patients, especially if doses higher than 30 mg per day are considered as required
For full dosing information please see the SPC
Method of administration for Intravesical use1
Access our full safety and monitoring information or please refer to section 4 of the SPC.
VELARIQ® is now available to prescribe in the UK. To arrange a visit with your local MEDICE UK Key Account Manager please click below.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.
Date of Preparation: August 2024 UK-VEL-2024-1644-v1
EXTERNAL LINK
You are now leaving the Medice UK website and are being directed to a website that contains information about Medice products, but which is not owned by Medice UK.
Please confirm you wish to follow this link.